Can Hepatitis Go Into Remission?
Yes, hepatitis B can achieve remission through both spontaneous immune control and antiviral treatment, with the ideal endpoint being sustained HBsAg loss (functional cure), though complete biochemical and virological remission on long-term therapy is a more commonly achievable goal.
Types of Remission in Hepatitis B
Inactive Carrier State (Spontaneous Remission)
The inactive HBV carrier state represents a form of spontaneous remission where the immune system achieves control of viral replication 1. This phase is characterized by:
- HBV DNA <2,000 IU/ml
- Persistently normal ALT levels (using traditional cut-off of ~40 IU/ml)
- HBeAg-negative with anti-HBe antibodies present
- Very low risk of cirrhosis or HCC in the majority of patients
Important caveat: This is not a permanent cure. The inactive carrier state confers a favorable long-term outcome, but progression to active chronic hepatitis B can still occur 1. Therefore, lifelong monitoring is required with ALT determinations at least every 6 months and periodic HBV DNA measurements 1.
Treatment-Induced Remission
Functional Cure (Ideal Endpoint)
HBsAg loss with or without anti-HBs seroconversion represents the optimal treatment endpoint 1, 2, 1, 3. This "functional cure" is associated with:
- Complete and definitive remission of chronic hepatitis B activity
- Improved long-term outcome
- Reduced risk of cirrhosis, decompensation, and HCC 1, 3
- Safe discontinuation of antiviral therapy
However, this endpoint is infrequently achievable with currently available antiviral agents 1. Spontaneous HBsAg loss occurs in only 1-3% of inactive carriers per year 1.
Sustained Off-Therapy Remission
For patients who don't achieve HBsAg loss, sustained off-therapy virological and biochemical response is a satisfactory endpoint 1:
- HBeAg-positive patients: Durable HBeAg seroconversion to anti-HBe with sustained undetectable HBV DNA for at least 12 months after stopping therapy 1, 2
- HBeAg-negative patients: Sustained HBV DNA <2,000 IU/ml for at least 12 months after therapy cessation 1
This has been shown to be associated with improved prognosis 1, 2, 1.
Maintained On-Therapy Remission
A more realistic endpoint for many patients is maintained virological remission (undetectable HBV DNA by sensitive PCR assay) under long-term antiviral therapy 1. This applies to:
- HBeAg-positive patients who don't achieve anti-HBe seroconversion
- HBeAg-negative patients (who have low rates of sustained off-therapy remission)
Critical Distinctions
HBeAg-Negative CHB vs. Inactive Carrier
This is a crucial and sometimes difficult distinction 1:
- Inactive carriers: Good prognosis, very low risk of complications
- HBeAg-negative CHB: Active liver disease with high risk of progression to cirrhosis and HCC
HBeAg-negative CHB is characterized by periodic reactivation with fluctuating HBV DNA and ALT levels 1. A minimum 1-year follow-up with ALT every 3-4 months and HBV DNA measurements is needed to distinguish between these states 1.
Monitoring Requirements
Even after achieving remission:
- Inactive carriers: ALT every 6 months after the first year, periodic HBV DNA levels 1
- After HBsAg loss before cirrhosis: Improved outcome but still requires monitoring
- After HBsAg loss with established cirrhosis: Patients remain at risk of HCC and require continued surveillance 1
Important Caveats
HBV cannot be completely eradicated due to persistence of covalently closed circular DNA (cccDNA) in hepatocyte nuclei 2
Reactivation risk: Even after HBsAg loss, immunosuppression may lead to HBV reactivation 1
HCC risk persists: Even after spontaneous HBsAg loss, HCC can still develop (annual rate ~0.55%), particularly if cirrhosis was present before HBsAg loss 3
Treatment discontinuation risks: Hepatitis flares may occur when treatment is stopped, particularly without HBeAg seroconversion 4
Hepatitis C Context
Unlike hepatitis B, hepatitis C is the first chronic viral infection that can be cured with direct-acting antivirals, achieving sustained virological response (SVR) representing true viral eradication in most cases 5. This represents a fundamentally different outcome than the "functional cure" achievable in hepatitis B.